European Primary Care Cardiovascular Society
In a randomized trial, a program of supervised and home-based exercise training significantly improved exercise test duration but had no effect on clinical events with similar effects across baseline physical activity tertiles in HFrEF patients.
EAPC Position Statement states that exercise programs for diabetics are a cost effective treatment and should be reimbursed
A network meta-analysis compared the SBP-lowering effectiveness of commonly prescribed antihypertensive treatments with structured exercise programs.
A position paper has been published by the Sports Cardiology section of the EAPC with updated recommendations on sports-participation in patients with CAD.
Real-world study suggests that rivaroxaban is associated with a lower risk of systemic embolism and stroke in NVAF patients taking ≥5 non-OAC medications. Polypharmacy did not affect risk of major bleeding.
A retrospective review showed that children with FH and family history of early-onset ASCVD were more likely to have Lp(a) ≥50 mg/dL, compared with children with FH and family history of late-onset ASCVD.
Prof. Hobbs stresses the importance of CVRM in primary care and how to manage this risk beyond glucose control.
A randomized study showed that a brief behavioral intervention can prevent weight gain over the Christmas period, for many a prolonged period of overeating and more sedentary behavior.
Slides with take home messages of our EPCCS Practical Guidance Document, which provides practical guidance on management of persons with dyslipidaemia in primary care, with a focus on challenges faced in clinical reality.
The strain imposed on the myocardium was compared in amateur endurance runners who completed a full marathon, a half-marathon or a 10-km race. The full marathon induced superior cardiac stress.
Community-based data show that increasing categories of severity of hypertension according to the 2017 ACC/AHA BP Guidelines are associated with increasing risk of CVD events in middle age.
A post-hoc analysis of the ARISTOTLE trial showed safety and efficacy of apixaban compared to warfarin in AF patients aged 55 years or older with multi-morbidity.
